Evaluation of antibody response after COVID‐19 vaccination of healthcare workers

• Published in: Journal of medical virology 2022-03, Vol.94 (3), p.1060-1066
• Main Authors: Uysal, Elif B., Gümüş, Sibel, Bektöre, Bayhan, Bozkurt, Hale, Gözalan, Ayşegül
• Format: Article
• Language: English
• Subjects: Age; Antibodies; Antibodies, Viral; Antibody Formation; Antibody response; Body mass; Body mass index; Body size; CoronaVac; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Dosage; Electrochemiluminescence; Evaluation; Female; Health care; Health Personnel; healthcare workers; Humans; Immune response; Immune system; Male; Medical personnel; Nucleocapsids; Proteins; receptor binding domain; SARS-CoV-2; seropositivity; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Smoking; Spike Glycoprotein, Coronavirus; Spike protein; Vaccination; Vaccines; Virology
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.27420

The common goal of all vaccines developed against COVID‐19, although they have been designed with different methods, is to develop an effective immunity and antibody response against SARS‐CoV‐2. However, the postvaccination immune response and antibody levels differ between individuals. This study examined the relationship between postvaccine seropositivity rates, age, gender, smoking, and body mass index (BMI), and antibody titers. A total of 314 healthcare workers (HCW) who were not previously infected with COVID‐19 and who had received two doses of CoronaVac inactivated vaccine participated in the study. Seropositivity against the receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein was measured from the participants 4 weeks after the second dose of vaccine using the electrochemiluminescence (ECLIA) method. In addition, the antibody developed against the nucleocapsid protein (NCP) was evaluated and compared using Elecsys Anti‐SARS‐CoV‐2 kit. One hundred and eighty‐one of the participants were female (57.6%) with a median age of 39 (interquartile range [IQR], 10) and 133 (42.4%) were male with a median age of 41 (IQR, 11). 99.6% of the volunteers developed seropositivity 4 weeks after the second dose of vaccine. It was also observed that the rate of RBD protein antibody titer was >250 U/ml in smokers, which is quite low compared to nonsmokers (p = 0.032), and that high RBD antibody titers were proportionally lower in obese participants, according to BMI values, compared to those with normal BMI (49.5% and 9.9%). It was observed that seropositivity developed in almost all participants after the CoronaVac vaccine. However, it was determined that the antibody titer measured varied depending on factors such as smoking, BMI, and duration.